These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37112972)

  • 21. The capsid revolution.
    Taylor IA; Fassati A
    J Mol Cell Biol; 2024 Apr; 15(11):. PubMed ID: 38037430
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HIV-1 capsid inhibitors: a sword to destroy the virus.
    Zhang X; Xu S; Sun L; Ding D; Tao Y; Kang D; Liu X; Zhan P
    Future Med Chem; 2022 May; 14(9):605-607. PubMed ID: 35297282
    [No Abstract]   [Full Text] [Related]  

  • 23. HIV-1 Resistance to the Capsid-Targeting Inhibitor PF74 Results in Altered Dependence on Host Factors Required for Virus Nuclear Entry.
    Zhou J; Price AJ; Halambage UD; James LC; Aiken C
    J Virol; 2015 Sep; 89(17):9068-79. PubMed ID: 26109731
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The HIV-1 Capsid-Targeted Inhibitor GSK878 Alters Selection of Target Sites for HIV DNA Integration.
    Marquis KA; Everett J; Cantu A; McFarland A; Sherrill-Mix S; Krystal M; Parcella K; Gillis E; Fridell RA; Bushman FD
    AIDS Res Hum Retroviruses; 2024 Feb; 40(2):114-126. PubMed ID: 37125442
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HLA-associated polymorphisms in the HIV-2 capsid highlight key differences between HIV-1 and HIV-2 immune adaptation.
    de Silva TI; Leligdowicz A; Carlson J; Garcia-Knight M; Onyango C; Miller N; Yindom LM; Hué S; Jaye A; Dong T; Cotten M; Rowland-Jones SL
    AIDS; 2018 Mar; 32(6):709-714. PubMed ID: 29369160
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation of naturally occurring HIV-1 resistance to DEB025 with capsid amino acid polymorphisms.
    Gallay PA; Ptak RG; Bobardt MD; Dumont JM; Vuagniaux G; Rosenwirth B
    Viruses; 2013 Mar; 5(3):981-97. PubMed ID: 23524389
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lenacapavir: First Approval.
    Paik J
    Drugs; 2022 Sep; 82(14):1499-1504. PubMed ID: 36272024
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lenacapavir: a twice-yearly treatment for adults with multidrug-resistant HIV infection and limited treatment options.
    Tuan J; Ogbuagu O
    Expert Rev Anti Infect Ther; 2023 Jun; 21(6):565-570. PubMed ID: 37067160
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Naturally Occurring Mutations in HIV-1 CRF01_AE Capsid Affect Viral Sensitivity to Restriction Factors.
    Nakayama EE; Saito A; Sultana T; Jin Z; Nohata K; Shibata M; Hosoi M; Motomura K; Shioda T; Sangkitporn S; Loket R; Saeng-Aroon S
    AIDS Res Hum Retroviruses; 2018 Apr; 34(4):382-392. PubMed ID: 29325426
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of Difference in Consensus Sequence between HIV-1 Subtype A/E and Subtype B Viruses on Elicitation of Gag-Specific CD8
    Zhang Y; Murakoshi H; Chikata T; Akahoshi T; Tran GV; Nguyen TV; Gatanaga H; Nguyen KV; Oka S; Kuse N; Takiguchi M
    J Virol; 2021 Feb; 95(6):. PubMed ID: 33361435
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Analysis of unusual and signature APOBEC-mutations in HIV-1 pol next-generation sequences.
    Tzou PL; Kosakovsky Pond SL; Avila-Rios S; Holmes SP; Kantor R; Shafer RW
    PLoS One; 2020; 15(2):e0225352. PubMed ID: 32102090
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacologic hyperstabilisation of the HIV-1 capsid lattice induces capsid failure.
    Faysal KMR; Walsh JC; Renner N; Márquez CL; Shah VB; Tuckwell AJ; Christie MP; Parker MW; Turville SG; Towers GJ; James LC; Jacques DA; Böcking T
    Elife; 2024 Feb; 13():. PubMed ID: 38347802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients.
    Verheyen J; Litau E; Sing T; Däumer M; Balduin M; Oette M; Fätkenheuer G; Rockstroh JK; Schuldenzucker U; Hoffmann D; Pfister H; Kaiser R
    Antivir Ther; 2006; 11(7):879-87. PubMed ID: 17302250
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Geographic and temporal trends in the molecular epidemiology and genetic mechanisms of transmitted HIV-1 drug resistance: an individual-patient- and sequence-level meta-analysis.
    Rhee SY; Blanco JL; Jordan MR; Taylor J; Lemey P; Varghese V; Hamers RL; Bertagnolio S; Rinke de Wit TF; Aghokeng AF; Albert J; Avi R; Avila-Rios S; Bessong PO; Brooks JI; Boucher CA; Brumme ZL; Busch MP; Bussmann H; Chaix ML; Chin BS; D'Aquin TT; De Gascun CF; Derache A; Descamps D; Deshpande AK; Djoko CF; Eshleman SH; Fleury H; Frange P; Fujisaki S; Harrigan PR; Hattori J; Holguin A; Hunt GM; Ichimura H; Kaleebu P; Katzenstein D; Kiertiburanakul S; Kim JH; Kim SS; Li Y; Lutsar I; Morris L; Ndembi N; Ng KP; Paranjape RS; Peeters M; Poljak M; Price MA; Ragonnet-Cronin ML; Reyes-Terán G; Rolland M; Sirivichayakul S; Smith DM; Soares MA; Soriano VV; Ssemwanga D; Stanojevic M; Stefani MA; Sugiura W; Sungkanuparph S; Tanuri A; Tee KK; Truong HM; van de Vijver DA; Vidal N; Yang C; Yang R; Yebra G; Ioannidis JP; Vandamme AM; Shafer RW
    PLoS Med; 2015 Apr; 12(4):e1001810. PubMed ID: 25849352
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Amino-acid co-variation in HIV-1 Gag subtype C: HLA-mediated selection pressure and compensatory dynamics.
    Rolland M; Carlson JM; Manocheewa S; Swain JV; Lanxon-Cookson E; Deng W; Rousseau CM; Raugi DN; Learn GH; Maust BS; Coovadia H; Ndung'u T; Goulder PJ; Walker BD; Brander C; Heckerman DE; Mullins JI
    PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients.
    Marcelin AG; Charpentier C; Jary A; Perrier M; Margot N; Callebaut C; Calvez V; Descamps D
    J Antimicrob Chemother; 2020 Jun; 75(6):1588-1590. PubMed ID: 32154864
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Different Effects of Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations on Cytotoxic T Lymphocyte Recognition between HIV-1 Subtype B and Subtype A/E Infections.
    Kuse N; Rahman MA; Murakoshi H; Tran GV; Chikata T; Koyanagi M; Nguyen KV; Gatanaga H; Oka S; Takiguchi M
    J Virol; 2015 Jul; 89(14):7363-72. PubMed ID: 25972553
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1.
    Handema R; Terunuma H; Kasolo F; Kasai H; Sichone M; Yamashita A; Deng X; Mulundu G; Ichiyama K; Munkanta M; Yokota T; Wakasugi N; Tezuka F; Yamamoto N; Ito M
    AIDS Res Hum Retroviruses; 2003 Feb; 19(2):151-60. PubMed ID: 12643279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV-1 B-subtype capsid protein: a characterization of amino acid's conservation and its significant association with integrase signatures.
    Dimonte S; Babakir-Mina M; Aquaro S
    Virus Genes; 2014 Jun; 48(3):429-37. PubMed ID: 24474329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fitness costs limit viral escape from cytotoxic T lymphocytes at a structurally constrained epitope.
    Peyerl FW; Bazick HS; Newberg MH; Barouch DH; Sodroski J; Letvin NL
    J Virol; 2004 Dec; 78(24):13901-10. PubMed ID: 15564498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.